Expression and significance of integrin alpha5, beta1 and E-CD in patients with non-small cell lung carcinoma.
- Author:
Qi-Sen GUO
1
;
Hui JIA
;
Ming-Yong HAN
;
Jin-Ming YU
;
Wei-Xia ZHONG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Cadherins; metabolism; Carcinoma, Non-Small-Cell Lung; metabolism; pathology; Female; Humans; Immunohistochemistry; Integrin alpha5beta1; metabolism; Lung Neoplasms; metabolism; pathology; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Smoking; Survival Analysis
- From: Chinese Journal of Oncology 2006;28(10):746-749
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the relationship between the expressions of integrin alpha5 beta1 and E-CD, and clinicopathological characteristics and prognosis of patients with non-small cell lung carcinoma (NSCLC).
METHODSThe expression of integrin alpha5 beta1 and E-CD were analyzed in 53 NSCLC and 12 control specimens by immunohistochemical assay.
RESULTSThe expression of integrin alpha5 beta1 was significantly higher in NSCLC (58.5%) than that in normal lung tissue (16.7%), and also positively related with pathological characteristics (P = 0.021), lymph node metastasis (P = 0.006), and clinical stage (P = 0.002). The 3-year survival rate in NSCLC group was significantly lower than that in control group (22.3% vs 40.6% , P = 0.041). The positive expression of E-CD in NSCLC and control group was 32.1% and 91.7%, respectively, and negatively correlated with pathological characteristics (P = 0.010) and lymph node metastasis (P = 0.002). The 3-year survival rate in control group was 19.9%, lower than that in NSCLC group (41.2%, P > 0.05), but the difference is not significant.
CONCLUSIONThe overexpression of integrin alpha5 beta1 may contribute to lymph node metastasis and play an inverse role, while E-CD may be a beneficial prognostic factor in patients with NSCLC.
